Thursday, November 12
Rocket Pharmaceuticals reported third-quarter 2026 results alongside regulatory and pipeline updates across its cardiovascular gene therapy programs.
SEC filing
Tuesday, October 6
The deal gives Rocket $35 million at closing, with more available in tranches tied to Danon disease program progress and Hercules's discretion.
SEC filing
Tuesday, September 15
The FDA confirmed a 12-patient pivotal population, a recalibrated dose, and 12-month co-primary endpoints for RP-A501 in Danon disease.
SEC filing